SEC Form 4 · accession 0001209191-15-001003
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Nicole R. Hadas
Officer — VP General Counsel & Secretary
Period of report
Jan 1, 2015
Accepted (ET)
Jan 5, 2015 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 1, 2015 | A | 4,539 | $11.64 | A | 74,752 | D | |
| Common StockF3,F4 | Jan 2, 2015 | S | 1,715 | $11.4607 | D | 73,037 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F172,623 shares of restricted stock (as adjusted from 41,499 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Twenty-five percent of the shares vested on December 2, 2014. The remaining shares vest in equal quarterly installments over the following three years until fully vested.
- F2Price represents the closing price of the Issuer's common stock on December 31, 2014.
- F3Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
- F4The price reported in this Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.25 to $11.64, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.